Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OH2 in Advanced Solid Tumors
NCT03866525Phase 2Recruiting
- Sponsor
- Wuhan Binhui Biopharmaceutical Co., Ltd.
- Start
- Apr 2019
- Primary completion
- Aug 2025
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
A Phase 2 trial of OH2 in solid tumor, sponsored by Wuhan Binhui Biopharmaceutical Co., Ltd.. Started Apr 2019; status: recruiting.
02
Drugs
OH2
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03866525.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03866525.